Hemoglobin variability with extended dosing of epoetin alfa in patients with chronic kidney disease and not on dialysis

Dialysis and Transplantation

Volumn 38, Issue 10, 2009, Pages 407-411

  Bailey, Robert A ^a   McGowan, Tracy ^a   Tang, K Linda ^a   Langholff, Wayne K ^a   Lantz, Keith C ^a   Wolfson, Marsha ^a  

^a CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIALYSIS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOSIS; TREATMENT OUTCOME;

EID: 70649111371     PISSN: 00902934     EISSN: None     Source Type: Journal    
DOI: 10.1002/dat.20365     Document Type: Article

References (13)

1. Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood). 2003;228:1-14.
2. McClellan W, Aronoff SL, Bolton WK, et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin. 2004;20:1501-1510. (Pubitemid 39361354)
3. Benz R, Schmidt R, Kelly K, Wolfson M. Epoetin alfa once every 2 weeks is effective for initiation of treatment of anemia of chronic kidney disease. Clin J Am Soc Nephrol. 2007;2:215-221.
4. Procrit (Epoetin alfa) for injection [package insert]. 2008. Raritan, NJ, Ortho Biotech Products, L.P.
5. Aranesp (darbepoetin alfa) for injection [package insert]. 2008. Thousand Oaks, CA, Amgen Inc.
6. Ebben JP, Gilbertson DT, Foley RN, Collins AJ. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol. 2006;1:1205-1210.
7. Spinowitz B, Germain M, Benz R, et al. A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease. Clin J Am Soc Nephrol. 2008;3(4):1015-1021.
8. Provenzano R, Bhaduri S, Singh AK. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. Clin Nephrol. 2005;64:113-123. (Pubitemid 41079007)
9. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int. 2005;68:1337-1343. (Pubitemid 43246455)
10. De NL, Conte G, Chiodini P, et al. Stability of target hemoglobin levels during the first year of epoetin treatment in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2007;2:938-946.
11. Yee J, Zasuwa G, Frinak S, Besarab A. Hemoglobin variability and hyporesponsiveness: much ado about something or nothing. Adv Chronic Kidney Dis. 2009;16:83-93.
12. Nissenson AR, Swan SK, Lindberg JS, et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis. 2002;40:110-118. (Pubitemid 34701218)
13. Sulowicz W, Locatelli F, Ryckelynck JP, et al. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol. 2007;2:637-646.